Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients

Comparison with multi-daily insulin injections therapy (MDI)

Giuseppe Derosa, Pamela Maffioli, Angela D'Angelo, Sibilla At Salvadeo, Ilaria Ferrari, Elena Fogari, Roberto Mereu, Alessia Gravina, Ilaria Palumbo, Sabrina Randazzo, Arrigo F G Cicero

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We compared the effects of continuous subcutaneous insulin infusion (CSII) and multi-daily insulin injections therapy (MDI) on glicemic control and on lipid profile in type 1 and type 2 diabetic patients. We divided the patients in two groups: in the first one (n=32) CSII was administered, in the second one (n=32) MDI was administered. HbA1c value was lower after 3, 6, 9, and 12 months with CSII compared to MDI. Fasting plasma glucose (FPG) value was lower with CSII after 3, 6, and 12 months compared to MDI. Post-prandial glucose (PPG) value was lower in the group with CSII after 3, 6, 9, and 12 months compared to MDI. A significant TC decrease was observed in the group treated with CSII at 9, and 12 months while a significant TC increase was observed with MDI at 6, and 12 months. A significant LDL-C decrease was obtained with CSII after 9, and 12 months while no significant changes were observed with MDI. A significant HDL-C increase was observed with CSII after 12 months. A significant Tg decrease was observed with CSII after 12 months while a significant Tg increase was observed with MDI at 6, and at 12 months. CSII therapy allows a faster and better achievement of the therapeutic target and also gives an improvement of the lipid profile.

Original languageEnglish
Pages (from-to)571-578
Number of pages8
JournalEndocrine Journal
Volume56
Issue number4
DOIs
Publication statusPublished - 2009

Fingerprint

Subcutaneous Infusions
Insulin
Injections
Therapeutics
Lipids
Glucose
Meals
Fasting

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients : Comparison with multi-daily insulin injections therapy (MDI). / Derosa, Giuseppe; Maffioli, Pamela; D'Angelo, Angela; At Salvadeo, Sibilla; Ferrari, Ilaria; Fogari, Elena; Mereu, Roberto; Gravina, Alessia; Palumbo, Ilaria; Randazzo, Sabrina; Cicero, Arrigo F G.

In: Endocrine Journal, Vol. 56, No. 4, 2009, p. 571-578.

Research output: Contribution to journalArticle

Derosa, Giuseppe ; Maffioli, Pamela ; D'Angelo, Angela ; At Salvadeo, Sibilla ; Ferrari, Ilaria ; Fogari, Elena ; Mereu, Roberto ; Gravina, Alessia ; Palumbo, Ilaria ; Randazzo, Sabrina ; Cicero, Arrigo F G. / Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients : Comparison with multi-daily insulin injections therapy (MDI). In: Endocrine Journal. 2009 ; Vol. 56, No. 4. pp. 571-578.
@article{769018ae2d014808bff7e27596d59bb3,
title = "Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: Comparison with multi-daily insulin injections therapy (MDI)",
abstract = "We compared the effects of continuous subcutaneous insulin infusion (CSII) and multi-daily insulin injections therapy (MDI) on glicemic control and on lipid profile in type 1 and type 2 diabetic patients. We divided the patients in two groups: in the first one (n=32) CSII was administered, in the second one (n=32) MDI was administered. HbA1c value was lower after 3, 6, 9, and 12 months with CSII compared to MDI. Fasting plasma glucose (FPG) value was lower with CSII after 3, 6, and 12 months compared to MDI. Post-prandial glucose (PPG) value was lower in the group with CSII after 3, 6, 9, and 12 months compared to MDI. A significant TC decrease was observed in the group treated with CSII at 9, and 12 months while a significant TC increase was observed with MDI at 6, and 12 months. A significant LDL-C decrease was obtained with CSII after 9, and 12 months while no significant changes were observed with MDI. A significant HDL-C increase was observed with CSII after 12 months. A significant Tg decrease was observed with CSII after 12 months while a significant Tg increase was observed with MDI at 6, and at 12 months. CSII therapy allows a faster and better achievement of the therapeutic target and also gives an improvement of the lipid profile.",
author = "Giuseppe Derosa and Pamela Maffioli and Angela D'Angelo and {At Salvadeo}, Sibilla and Ilaria Ferrari and Elena Fogari and Roberto Mereu and Alessia Gravina and Ilaria Palumbo and Sabrina Randazzo and Cicero, {Arrigo F G}",
year = "2009",
doi = "10.1507/endocrj.K08E-330",
language = "English",
volume = "56",
pages = "571--578",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients

T2 - Comparison with multi-daily insulin injections therapy (MDI)

AU - Derosa, Giuseppe

AU - Maffioli, Pamela

AU - D'Angelo, Angela

AU - At Salvadeo, Sibilla

AU - Ferrari, Ilaria

AU - Fogari, Elena

AU - Mereu, Roberto

AU - Gravina, Alessia

AU - Palumbo, Ilaria

AU - Randazzo, Sabrina

AU - Cicero, Arrigo F G

PY - 2009

Y1 - 2009

N2 - We compared the effects of continuous subcutaneous insulin infusion (CSII) and multi-daily insulin injections therapy (MDI) on glicemic control and on lipid profile in type 1 and type 2 diabetic patients. We divided the patients in two groups: in the first one (n=32) CSII was administered, in the second one (n=32) MDI was administered. HbA1c value was lower after 3, 6, 9, and 12 months with CSII compared to MDI. Fasting plasma glucose (FPG) value was lower with CSII after 3, 6, and 12 months compared to MDI. Post-prandial glucose (PPG) value was lower in the group with CSII after 3, 6, 9, and 12 months compared to MDI. A significant TC decrease was observed in the group treated with CSII at 9, and 12 months while a significant TC increase was observed with MDI at 6, and 12 months. A significant LDL-C decrease was obtained with CSII after 9, and 12 months while no significant changes were observed with MDI. A significant HDL-C increase was observed with CSII after 12 months. A significant Tg decrease was observed with CSII after 12 months while a significant Tg increase was observed with MDI at 6, and at 12 months. CSII therapy allows a faster and better achievement of the therapeutic target and also gives an improvement of the lipid profile.

AB - We compared the effects of continuous subcutaneous insulin infusion (CSII) and multi-daily insulin injections therapy (MDI) on glicemic control and on lipid profile in type 1 and type 2 diabetic patients. We divided the patients in two groups: in the first one (n=32) CSII was administered, in the second one (n=32) MDI was administered. HbA1c value was lower after 3, 6, 9, and 12 months with CSII compared to MDI. Fasting plasma glucose (FPG) value was lower with CSII after 3, 6, and 12 months compared to MDI. Post-prandial glucose (PPG) value was lower in the group with CSII after 3, 6, 9, and 12 months compared to MDI. A significant TC decrease was observed in the group treated with CSII at 9, and 12 months while a significant TC increase was observed with MDI at 6, and 12 months. A significant LDL-C decrease was obtained with CSII after 9, and 12 months while no significant changes were observed with MDI. A significant HDL-C increase was observed with CSII after 12 months. A significant Tg decrease was observed with CSII after 12 months while a significant Tg increase was observed with MDI at 6, and at 12 months. CSII therapy allows a faster and better achievement of the therapeutic target and also gives an improvement of the lipid profile.

UR - http://www.scopus.com/inward/record.url?scp=68449090863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449090863&partnerID=8YFLogxK

U2 - 10.1507/endocrj.K08E-330

DO - 10.1507/endocrj.K08E-330

M3 - Article

VL - 56

SP - 571

EP - 578

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 4

ER -